Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Travere Therapeutics Inc shares valued at $8,263 were sold by Cline Christopher R. on Sep 03 ’25. At $18.20 per share, Cline Christopher R. sold 454 shares. The insider’s holdings dropped to 92,202 shares worth approximately $2.18 million following the completion of this transaction.
Also, Cline Christopher R. sold 119 shares, netting a total of over 2,345 in proceeds. Following the sale of shares at $19.71 each, the insider now holds 92,083 shares.
Before that, Cline Christopher R. had sold 470 shares from its account. In a trade valued at $8,136, the CHIEF FINANCIAL OFFICER traded Travere Therapeutics Inc shares for $17.31 each. Upon closing the transaction, the insider’s holdings decreased to 470 shares, worth approximately $2.19 million.
Analysts at Citigroup resumed the stock at ‘”a Buy”‘ outlook in a report released in mid June. As of January 10, 2025, Cantor Fitzgerald has initiated its “an Overweight” rating for TVTX. Earlier on October 21, 2024, Wells Fargo upgraded its rating. Their new recommendation was “an Overweight” for TVTX stock which previously was a “an Equal weight”.
Analyzing TVTX Stock Performance
On last trading session, Travere Therapeutics Inc [NASDAQ: TVTX] rose 3.86% to $23.65. The stock’s lowest price that day was $22.65, but it reached a high of $23.76 in the same session. During the last five days, there has been a drop of approximately -13.40%. Over the course of the year, Travere Therapeutics Inc shares have jumped approximately 75.45%.
Is Travere Therapeutics Inc subject to short interest?
Stocks of Travere Therapeutics Inc saw a sharp rise in short interest on 2025-08-29 jumping by 1.46 million shares to 12.08 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 10.62 million shares. A jump of 12.06% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.46 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.46.
Which companies own the most shares of Travere Therapeutics Inc (TVTX)?
In terms of Travere Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 35 in the next 12 months, up nearly 53.71% from the previous closing price of $22.77. Analysts anticipate Travere Therapeutics Inc stock to reach 35 by 2025, with the lowest price target being 35. In spite of this, 8 analysts ranked Travere Therapeutics Inc stock as Buy at the end of 2025.
